Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and bevacizumab plus chemotherapy were effective for EGFR-mutant patients. However, the appropriated treatment orders remained controvertible. We investigated the efficacy of treatment orders between bevacizumab plus...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Transl Oncol
Main Authors: Chen, R.-L., Chen, H.-J., Jiang, B.-Y., Zhang, X.-C., Zhou, Q., Tu, H.-Y., Zhong, W.-Z., Wu, Y.-L., Yang, J.-J.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2017
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5797192/
https://ncbi.nlm.nih.gov/pubmed/28702789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12094-017-1714-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki